Coric, Vladimir, Salloway, Stephen, van Dyck, Christopher H., Dubois, Bruno, Andreasen, Niels, Brody, Mark, Curtis, Craig, Soininen, Hilkka, Thein, Stephen, Shiovitz, Thomas, Pilcher, Gary, Ferris, Steven, Colby, Susan, Kerselaers, Wendy, Dockens, Randy, Soares, Holly, Kaplita, Stephen, Luo, Feng, Pachai, Chahin, Bracoud, Luc, Mintun, Mark, Grill, Joshua D., Marek, Ken, Seibyl, John, Cedarbaum, Jesse M., Albright, Charles, Feldman, Howard H., Berman, Robert M.

Importance: Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to assess potential disease-modifying agents in clinical trials. To our knowledge, this is the first report of a randomized trial to prospectively enrich a study population with prodromal AD (PDAD) defined by cerebrospinal fluid (CSF) biomarker criteria and mild […]

Salloway, Stephen, Sperling, Reisa, Fox, Nick C., Blennow, Kaj, Klunk, William, Raskind, Murray, Sabbagh, Marwan, Honig, Lawrence S., Porsteinsson, Anton P., Ferris, Steven, Reichert, Marcel, Ketter, Nzeera, Nejadnik, Bijan, Guenzler, Volkmar, Miloslavsky, Maja, Wang, Daniel, Lu, Yuan, Lull, Julia, Tudor, Iulia Cristina, Liu, Enchi, Grundman, Michael, Yuen, Eric, Black, Ronald, Brashear, H. Robert

Background: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease.; Methods: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer’s disease–one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying […]

Nair, Balakrishnan Kichu, Heim, Christian, Krishnan, Chitra, D'Este, Catherine, Marley, John, Attia, John

Aim: To study the effect of Baroque music in people with dementia.; Methods: Patients in a multicultural dementia-specific aged care facility were subjected to Baroque music in a cross-over study.; Results: There were significantly more behavioural disturbances during the weeks when Baroque music was played compared to control periods (0.2 more episodes per week, P […]

Haïk, Stéphane, Marcon, Gabriella, Mallet, Alain, Tettamanti, Mauro, Welaratne, Arlette, Giaccone, Giorgio, Azimi, Shohreh, Pietrini, Vladimiro, Fabreguettes, Jean-Roch, Imperiale, Daniele, Cesaro, Pierre, Buffa, Carlo, Aucan, Christophe, Lucca, Ugo, Peckeu, Laurène, Suardi, Silvia, Tranchant, Christine, Zerr, Inga, Houillier, Caroline, Redaelli, Veronica, Vespignani, Hervé, Campanella, Angela, Sellal, François, Krasnianski, Anna, Seilhean, Danielle, Heinemann, Uta, Sedel, Frédéric, Canovi, Mara, Gobbi, Marco, Di Fede, Giuseppe, Laplanche, Jean-Louis, Pocchiari, Maurizio, Salmona, Mario, Forloni, Gianluigi, Brandel, Jean-Philippe, Tagliavini, Fabrizio

Background: Creutzfeldt-Jakob disease (CJD) is a fatal, untreatable prion encephalopathy. Previous studies showed that doxycycline is effective in in-vitro and in-vivo models of disease, and patients with CJD who received compassionate treatment with doxycycline showed increased survival time compared with historical series. We therefore did a randomised, double-blind study of doxycycline versus placebo in CJD.; […]

Eggermont, L H P, Swaab, D F, Hol, E M, Scherder, E J A

Background: Walking has proven to be beneficial for cognition in healthy sedentary older people. The aim of this study was to examine the effects of a walking intervention on cognition in older people with dementia.; Methods: 97 older nursing home residents with moderate dementia (mean age 85.4 years; 79 female participants; mean Mini-Mental State Examination […]

Doody, Rachelle S., Raman, Rema, Farlow, Martin, Iwatsubo, Takeshi, Vellas, Bruno, Joffe, Steven, Kieburtz, Karl, He, Feng, Sun, Xiaoying, Thomas, Ronald G., Aisen, Paul S, Siemers, Eric, Sethuraman, Gopalan, Mohs, Richard

Background: Alzheimer’s disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer’s disease.; Methods: We conducted a double-blind, placebo-controlled trial in which 1537 patients […]